All In Biotech

Drug Trial Radar · NCT07611357

[18F]F-AraG PET Imaging in Alzheimer's Disease

Total-Body [18F]F-AraG PET/CT Imaging to Quantify CNS and Systemic T Cell Involvement in Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

May 16, 2026

Primary completion

Sep 16, 2029

Study completion Dec 16, 2029

Sponsor

Lead sponsor
CellSight Technologies, Inc.Industry
Sponsor type
Industry
Collaborators
University of California, Davis
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the use of \[18F\]F-AraG PET/CT imaging to quantify activated T cell involvement in patients with Alzheimer's disease (AD). Participants will undergo total-body dynamic PET imaging to assess tracer uptake in the brain and peripheral organs. Results will be compared between participants with AD and healthy controls to characterize both central nervous system and systemic immune alterations in AD

Conditions

  • Alzheimer Disease (AD)

Interventions

  • Drug: [18F]F-AraG (PET tracer)Drug

    Dose: \~5 mCi IV bolus. Procedure: Total-body PET/CT dynamic imaging. Blood samples will be collected during scan.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [¹⁸F]F-AraG uptake in the brain of patients with ADTime frame: Imaging visit (~70 minutes)
  2. [¹⁸F]F-AraG uptake kinetics in the brain of patients with ADTime frame: Imaging visit (~70 minutes)
  3. [¹⁸F]F-AraG vascular kinetics in the brain of patients with ADTime frame: Imaging visit (~70 minutes)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.